215 related articles for article (PubMed ID: 18483270)
1. Cancer immunotherapy using in vitro genetically modified targeted dendritic cells.
Wei H; Wang H; Lu B; Li B; Hou S; Qian W; Fan K; Dai J; Zhao J; Guo Y
Cancer Res; 2008 May; 68(10):3854-62. PubMed ID: 18483270
[TBL] [Abstract][Full Text] [Related]
2. Genetically targeted T cells eradicate established breast cancer in syngeneic mice.
Wang H; Wei H; Zhang R; Hou S; Li B; Qian W; Zhang D; Kou G; Dai J; Guo Y
Clin Cancer Res; 2009 Feb; 15(3):943-50. PubMed ID: 19188165
[TBL] [Abstract][Full Text] [Related]
3. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity.
Balkow S; Loser K; Krummen M; Higuchi T; Rothoeft T; Apelt J; Tuettenberg A; Weishaupt C; Beissert S; Grabbe S
Exp Dermatol; 2009 Jan; 18(1):78-87. PubMed ID: 19054060
[TBL] [Abstract][Full Text] [Related]
5. Potent in vivo anti-tumor activity of isolated CD62L(low) lymph node cells sensitized in vivo with tumor lysate-pulsed DC-based vaccines.
Liu Z; Fan H; Wu Y; Chen B
Cytotherapy; 2005; 7(4):353-62. PubMed ID: 16162457
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
Nukiwa M; Andarini S; Zaini J; Xin H; Kanehira M; Suzuki T; Fukuhara T; Mizuguchi H; Hayakawa T; Saijo Y; Nukiwa T; Kikuchi T
Eur J Immunol; 2006 Apr; 36(4):1019-27. PubMed ID: 16525992
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic effects of treatment of pancreatic carcinoma by interleukin-23 and apoptotic cell antigen-modified dendritic cell vaccine: experiment with mice].
Tan G; Wang ZY; Yin S
Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(14):943-6. PubMed ID: 16759530
[TBL] [Abstract][Full Text] [Related]
8. Adenoviral gene transfer of stromal cell-derived factor-1 to murine tumors induces the accumulation of dendritic cells and suppresses tumor growth.
Fushimi T; O'Connor TP; Crystal RG
Cancer Res; 2006 Apr; 66(7):3513-22. PubMed ID: 16585175
[TBL] [Abstract][Full Text] [Related]
9. Appropriate timing of CD40 ligation for RNA-Pulsed DCs to induce antitumor immunity.
Miura S; Kagamu H; Tanaka H; Yoshizawa H; Gejyo F
Scand J Immunol; 2008 Apr; 67(4):385-91. PubMed ID: 18282232
[TBL] [Abstract][Full Text] [Related]
10. Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy.
Saji H; Song W; Furumoto K; Kato H; Engleman EG
Clin Cancer Res; 2006 Apr; 12(8):2568-74. PubMed ID: 16638867
[TBL] [Abstract][Full Text] [Related]
11. Increased survival and decreased tumor size due to intratumoral injection of ethanol followed by administration of immature dendritic cells.
Kumagi T; Akbar SM; Horiike N; Onji M
Int J Oncol; 2003 Oct; 23(4):949-55. PubMed ID: 12963973
[TBL] [Abstract][Full Text] [Related]
12. Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo.
Hanks BA; Jiang J; Singh RA; Song W; Barry M; Huls MH; Slawin KM; Spencer DM
Nat Med; 2005 Feb; 11(2):130-7. PubMed ID: 15665830
[TBL] [Abstract][Full Text] [Related]
13. siRNA specific delivery system for targeting dendritic cells.
Zheng X; Vladau C; Shunner A; Min WP
Methods Mol Biol; 2010; 623():173-88. PubMed ID: 20217551
[TBL] [Abstract][Full Text] [Related]
14. Modification of dendritic cells with interferon-gamma-inducible protein-10 gene to enhance vaccine potency.
Kang TH; Bae HC; Kim SH; Seo SH; Son SW; Choi EY; Seong SY; Kim TW
J Gene Med; 2009 Oct; 11(10):889-98. PubMed ID: 19618483
[TBL] [Abstract][Full Text] [Related]
15. Neuroblastoma-induced inhibition of dendritic cell IL-12 production via abrogation of CD40 expression.
Walker SR; Redlinger RE; Barksdale EM
J Pediatr Surg; 2005 Jan; 40(1):244-9; discussion 249-50. PubMed ID: 15868592
[TBL] [Abstract][Full Text] [Related]
16. Bacteriophages support anti-tumor response initiated by DC-based vaccine against murine transplantable colon carcinoma.
Pajtasz-Piasecka E; Rossowska J; Duś D; Weber-Dabrowska B; Zabłocka A; Górski A
Immunol Lett; 2008 Feb; 116(1):24-32. PubMed ID: 18166233
[TBL] [Abstract][Full Text] [Related]
17. Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10.
Motomura Y; Senju S; Nakatsura T; Matsuyoshi H; Hirata S; Monji M; Komori H; Fukuma D; Baba H; Nishimura Y
Cancer Res; 2006 Feb; 66(4):2414-22. PubMed ID: 16489048
[TBL] [Abstract][Full Text] [Related]
18. Tumor-specific dendritic cells generated by genetic redirection of Toll-like receptor signaling against the tumor-associated antigen, erbB2.
Xu Y; Darcy PK; Kershaw MH
Cancer Gene Ther; 2007 Sep; 14(9):773-80. PubMed ID: 17599092
[TBL] [Abstract][Full Text] [Related]
19. Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer.
Kao JY; Zhang M; Chen CM; Chen JJ
Immunol Lett; 2005 Nov; 101(2):154-9. PubMed ID: 15993950
[TBL] [Abstract][Full Text] [Related]
20. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine.
den Brok MH; Sutmuller RP; Nierkens S; Bennink EJ; Toonen LW; Figdor CG; Ruers TJ; Adema GJ
Cancer Res; 2006 Jul; 66(14):7285-92. PubMed ID: 16849578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
